N
ACAD icon

Natixis’s Acadia Pharmaceuticals ACAD Stock Holding History

Natixis’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$16 – 972
2022
Q4 		$16 Buy
+1
New +$16 ﹤0.01% 1065
2022
Q1 		– Sell
-579,961
Closed -$13.5M – 1145
2021
Q4 		$13.5M Buy
579,961
+409,300
+240% +$8.23M 0.05% 317
2021
Q3 		$2.83M Buy
170,661
+158,896
+1,351% +$3.06M 0.01% 662
2021
Q2 		$287K Buy
+11,765
New +$266K ﹤0.01% 789
2021
Q1 		– Sell
-170,240
Closed -$9.1M – 1052
2020
Q4 		$9.1M Buy
+170,240
New +$8.45M 0.03% 415
2018
Q3 		– Sell
-22,565
Closed -$345K – 770
2018
Q2 		$345K Buy
+22,565
New +$402K ﹤0.01% 742
2018
Q1 		– Sell
-12,489
Closed -$376K – 881
2017
Q4 		$376K Sell
12,489
-21,113
-63% -$675K ﹤0.01% 642
2017
Q3 		$1.27M Buy
+33,602
New +$1.09M 0.01% 482

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Natixis's ACAD Position: Q1 2023 in Review

Natixis sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 1 share — an estimated $16 sold.

Natixis first reported a position in ACAD in Q3 2017 and held it in 8 quarters. The position peaked at $13.5M in Q4 2021. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

  • Natixis reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Natixis sold 1 Acadia Pharmaceuticals share in Q1 2023, an estimated $16.
  • Natixis first reported a position in Acadia Pharmaceuticals in Q3 2017 and held it in 8 quarters.
  • Natixis's Acadia Pharmaceuticals position peaked at $13.5M in Q4 2021.
  • 233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Natixis's 13F filing for Q1 2023, filed 12 May 2023.